MazdutideEli Lilly & Innovent BiologicsInsurance Coverage Outlook

Formulary Tier: Type 2 Diabetes

Expected Tier 3 (Preferred Brand) on most commercial plans, similar to Mounjaro (96% coverage, Tier 3 placement). Copays likely $50-$150/month. Manufacturer savings programs expected at launch (similar to Mounjaro's $25/month copay card).

Formulary Tier: Obesity

Expected Tier 4 (Specialty Tier) following Zepbound patterns. Higher copays expected ($150-$300+/month). Coverage more common among very large employers (5,000+ workers: 43% currently cover GLP-1s) than mid-size employers (200-999 workers: 16%).^[1]

Prior Authorization: Diabetes

Most plans expected to require PA with A1C ≥7% (some plans ≥8%), documented metformin failure (3-6 months), and no contraindications. Most employer and ACA plans must decide a PA within 15 days (72 hours if urgent); many decide sooner.

Prior Authorization: Obesity

PA expected on plans that cover it with BMI ≥30 (or ≥27 with comorbidities like hypertension, dyslipidemia, obstructive sleep apnea), 6-12 months lifestyle interventions documented (diet, exercise, behavioral counseling), and failure of lower-cost weight-loss medications (phentermine, naltrexone/bupropion).

Step Therapy (Fail-First Requirements)

Diabetes: Most plans require metformin failure (3-6 months) before approving any GLP-1 or dual-agonist. Some plans may require sulfonylurea or DPP-4 inhibitor failure as well.
Obesity: May require trying phentermine or other lower-cost options before dual-agonist approval. Some plans may require failure of GLP-1-only drugs (Wegovy, oral semaglutide) before approving dual-agonists. Can delay access 6-12 months.

Type 2 Diabetes - EXPECTED HIGH COVERAGE

Most Part D Plans expected to cover mazdutide for type 2 diabetes, similar to Mounjaro (96% coverage) and Ozempic (94% coverage). Likely Tier 3, with prior authorization expected (A1C ≥7%, metformin failure). 2026 out-of-pocket cap: $2,100 annually (Inflation Reduction Act). Copays vary by plan and coverage phase (deductible, initial coverage, catastrophic).

Obesity - EXCLUDED BY LAW (BUT POLICY MAY CHANGE)

Federal Law Currently Prohibits Coverage
Basic Medicare Part D coverage excludes weight loss drugs under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. As of January 2025, mazdutide for obesity would NOT be covered if approved, unless Congress changes the law.

Recent Policy Developments (November 2025)

After the November 6, 2025 announcement,^[2] CMS launched the Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027). It covers only Wegovy (injection and pill), Foundayo, and the Zepbound KwikPen for weight loss, for $50 per monthly fill with conditions. Mazdutide is not a Bridge drug, and CMS has not announced what replaces the Bridge after December 31, 2027. Mazdutide could still qualify for Part D coverage under another medically accepted use (for example, if FDA approves it for CVD risk reduction).

Why the Exclusion Exists

The 2003 law specifically excludes "drugs used for weight loss" from Part D. This means Part D plans cover the same drug (e.g., semaglutide) for diabetes (Ozempic) but not for weight loss alone (Wegovy); Wegovy's weight-loss coverage comes only through the separate Medicare GLP-1 Bridge.

Will This Change by 2028-2030?

Congressional bills (e.g., Treat and Reduce Obesity Act) have been proposed to expand Medicare coverage for obesity medications, but none have passed as of January 2025. By mazdutide's expected US approval (2028-2030), policy may evolve, especially if dual-agonists demonstrate cardiovascular benefits qualifying them as "cardioprotective" rather than just "weight loss" drugs. Bottom line: Medicare diabetes coverage likely; obesity coverage uncertain, dependent on Congressional/CMS action between now and 2028-2030.

Type 2 Diabetes - Most States Expected to Cover

Most state Medicaid programs expected to cover mazdutide for type 2 diabetes with prior authorization, similar to Mounjaro and Ozempic coverage patterns. Typical criteria: A1C ≥7% or ≥8% (varies by state), metformin failure documented (3-6 months), no contraindications (pancreatitis history, MEN2 syndrome, medullary thyroid cancer). Check your state's Preferred Drug List (PDL).

Obesity - Very Limited Coverage Expected

Only 13 states (as of January 2026) covered GLP-1s for obesity in Medicaid.^[3] By mazdutide's expected approval (2028-2030), coverage may expand modestly, but most states will likely continue excluding obesity medications due to budget constraints. Dual-agonist mechanism may help if mazdutide demonstrates cost-effectiveness (reduced diabetes/CVD incidence offsetting drug costs).

States with Current GLP-1 Obesity Coverage (More Likely to Cover Mazdutide)

California, Pennsylvania, North Carolina, Louisiana, Minnesota, and a few other states provide some Medicaid coverage for GLP-1s for obesity (as of 2024-2025). Typically requires BMI ≥30 (or ≥27 with comorbidities like hypertension, dyslipidemia, obstructive sleep apnea), 6-12 months lifestyle interventions (diet, exercise, behavioral counseling), behavioral program participation (often mandatory), and quarterly follow-up appointments.

States Without Obesity Coverage (Unlikely to Cover Mazdutide)

Most state Medicaid programs exclude obesity medications entirely, classifying them as "cosmetic" or "lifestyle" drugs rather than medical necessity. This may change slowly as evidence for long-term health benefits (CVD reduction, diabetes prevention) grows, but budget pressures limit expansion. By 2028-2030, expect gradual expansion but not universal coverage.

How to Check Your State's Coverage

Action Steps:
1. Visit your state Medicaid website (e.g., "California Medi-Cal", "New York Medicaid")
2. Search for "Preferred Drug List" (PDL) or "Formulary"
3. Look under "Endocrine" or "Diabetes" categories for GLP-1 receptor agonists
4. Check "Weight Loss" or "Obesity" categories (if they exist)
5. Review prior authorization criteria for your state
6. Call Medicaid member services for clarification (formularies can be complex)

What It Is: Prior authorization requires your doctor to submit clinical documentation to your insurance company before they'll approve coverage. The insurer reviews your medical history, BMI, A1C, comorbidities, and prior treatments to determine if mazdutide is "medically necessary."

Why It Exists: Insurers use PA to control costs and ensure medications are used appropriately. For expensive medications like dual-agonists (expected $900-$1,200/month retail), PA helps prevent off-label use and ensures patients meet clinical criteria.

How to Overcome:

• Work with your doctor to submit a complete PA form with all required documentation
• Include a detailed letter of medical necessity explaining why mazdutide is appropriate (e.g., dual-agonist mechanism needed for superior efficacy)
• Document your BMI, weight-related comorbidities (hypertension, dyslipidemia, obstructive sleep apnea, prediabetes), and prior weight-loss attempts (lifestyle interventions, medications tried and failed)
• For diabetes: Document A1C ≥7%, metformin failure (3-6 months), and why dual-agonist is preferred over GLP-1-only options
• If denied, appeal immediately with additional supporting evidence (clinical studies showing mazdutide superiority, endocrinologist letter)
• Consider using Honest Care's appeal service to improve approval chances with expert guidance

What It Is: Step therapy requires you to try and fail less expensive treatments before your insurer will approve mazdutide. For diabetes: typically metformin first, possibly sulfonylureas or DPP-4 inhibitors. For obesity: may require phentermine, naltrexone/bupropion, or even GLP-1-only drugs (Wegovy, oral semaglutide) before approving dual-agonists.

Why It Exists: Step therapy controls costs by ensuring patients start with lower-cost interventions. If those work, expensive medications aren't needed. If they don't, the insurer has documentation justifying the upgrade to dual-agonists.

How to Overcome:

• Document prior treatment failures thoroughly (medications tried, duration, outcomes, why they failed or caused intolerable side effects)
• Request a step therapy exception if you have contraindications to required first-line drugs (e.g., metformin contraindicated due to kidney disease)
• Demonstrate medical urgency (e.g., uncontrolled diabetes with A1C ≥9%, severe obesity with multiple comorbidities requiring aggressive intervention)
• For obesity: Show why dual-agonist is preferable to GLP-1-only options (e.g., failed Wegovy trial, need for superior efficacy demonstrated in GLORY-1 trial)
• Provide evidence from clinical trials (GLORY-1 showing mazdutide superiority over semaglutide in head-to-head comparison: 10.29% vs 6.00% weight loss at 32 weeks)^[6]

What It Is: Quantity limits restrict how much medication you can receive per fill (e.g., 30-day supply only, no 90-day fills). This forces more frequent refills and pharmacy visits. For mazdutide (weekly injection), this means 4 pens per fill (1 month) rather than 12 pens (3 months).

Why It Exists: Insurers use quantity limits to monitor high-cost medication use and reduce waste. For dual-agonists, limits also ensure patients are actively using the medication and attending follow-up visits (quarterly weight checks, A1C monitoring).

How to Overcome:

• Request a quantity limit override if 30-day supplies are inconvenient (e.g., you travel frequently, live in remote area with limited pharmacy access)
• Use mail-order or specialty pharmacies that may allow 90-day supplies for maintenance medications
• Set up automatic refills to avoid lapses in coverage (missing doses can reduce efficacy)
• Demonstrate adherence with refill history (if you've been compliant with 30-day fills for 3-6 months, request upgrade to 90-day)

What It Is: Some plans completely exclude certain medications from coverage, meaning no amount of appeals or documentation will result in approval. This is becoming more common for weight-loss drugs as costs rise. Some employers exclude entire drug classes (all GLP-1s, all dual-agonists) for obesity indication.

Why It Exists: Employers and insurers may exclude obesity medications to control costs, especially if they consider obesity a "lifestyle" condition rather than a medical disease. Budget pressures are significant: one large retailer projected $1.2 million annually in GLP-1 costs for obesity coverage.^[1]

How to Overcome:

• Check your plan's formulary to confirm mazdutide coverage for your indication (diabetes vs obesity) BEFORE starting treatment
• If obesity indication is excluded, appeal to your employer's HR department for formulary changes during annual open enrollment (provide clinical evidence, cost-effectiveness data showing long-term savings from diabetes/CVD prevention)
• Consider switching plans during open enrollment if your current plan excludes obesity medications (compare plans on healthcare.gov or employer benefits portal)
• Explore manufacturer savings programs when mazdutide launches (similar to Mounjaro's $25/month copay card for commercial insurance, patient assistance for uninsured)
• For obesity patients: If you also have prediabetes, cardiovascular risk factors, or NAFLD, emphasize those comorbidities in appeals rather than weight loss alone (reframe as "metabolic disease" vs "cosmetic weight loss")
• Join patient advocacy efforts to expand coverage (e.g., Obesity Action Coalition, American Diabetes Association advocacy)